Navigation Links
Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
Date:1/15/2008

Collaboration with CDC to Focus on Testing of Juvaris JVRS-100 as an Adjuvant with existing H5N1 vaccine for dose-sparing and cross protection

PLEASANTON, Calif., Jan. 15 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today that The Centers for Disease Control and Prevention and Juvaris BioTherapeutics, Inc. have entered into a Cooperative Research and Development Agreement (CRADA) for the evaluation of a JVRS-100 adjuvanted H5N1 pandemic influenza vaccine. The ability of JVRS-100 to aid in the induction of a protective antibody response to the H5N1 vaccine at low doses of vaccine will be confirmed. This collaborative study will determine if the use of the Juvaris JVRS-100 adjuvant will extend the limited supply of H5N1 vaccines in the event of a pandemic.

In preparation for the possibility of an influenza pandemic caused by an H5N1 avian influenza virus that has obtained the ability to be easily transmitted from person to person, several strains of H5N1 viruses have been used to prepare killed-virus vaccines. Vaccine trials in people testing the immunogenicity of these pre-pandemic vaccines have shown that high vaccine doses are required to produce an antibody response that is believed to be protective. In order to lower the dose of vaccine and extend the supply of available vaccine, a number of immune boosters known as adjuvants are being tested.

"Although the principal commercial value of JVRS-100 will be as a mono-immunotherapy, we are pleased to enter into this CRADA with CDC for testing of the JVRS-100 as an adjuvant for potential extension of the current supply of H5N1 vaccine," said Martin D. Cleary, Co-founder, President and CEO of Juvaris. "In preclinical studies using seasonal influenza vaccine our adjuvant can decrease the amount of vaccine necessary to induce protective antibody immunity up to fifty-fold, which would be beneficial in case of limited vaccine supply during an influenza pandemic. Furthermore, preclinical experiments with inactivated virus have shown greater cross-protection when our adjuvant is used."

About Juvaris

Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.

When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which there are significant unmet medical needs.

The Company recently completed a Series A financing with Kleiner Perkins Caufield & Byers as the sole investor. It plans to start up to four clinical studies in 2008. The first will be a prophylactic vaccine for Influenza A, the second a therapy for chronic Hepatitis B, the third for chronic Hepatitis C and a fourth for Acute Myelogenous Leukemia (AML).

The Company encourages partnering inquiries and can be reached at its website @ http://www.juvaris.com.

Company Contact:

Martin D. Cleary

Juvaris BioTherapeutics, Inc.

925.399.6200

mdcleary@juvaris.com


'/>"/>
SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 Report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through ... markets. Market data and analytics are derived from primary and ...
(Date:2/24/2017)... -- ITL Limited, ( ASX : ITD ), une société ... les excellents résultats semestriels clos le 31 décembre 2016 ... complète « Résultats et mise à jour sur la croissance ... Faits marquants ... en hausse de 104 %) Bénéfice par ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... which specializes in thought leadership , media relations, social media, content marketing ... that will be powered through Act-On, an intuitive marketing automation platform. , Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... Justice jointly issued a letter to withdraw previous guidance issued by ... gender identity. The guidance issued in May 2016 by the Obama Administration came ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) ... Meeting. KLS is a longtime supporter of the event. , "We are pleased ... Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track ...
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):